Caprylidene
From Self-sufficiency
| 260px | |
| 260px | |
| Systematic (IUPAC) name | |
|---|---|
|
[2-octanoyloxy-1-(octanoyloxymethyl)ethyl] octanoate | |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| ATC code | None |
| PubChem | CID 10850 |
| ChemSpider | 10393 |
| Synonyms | Glycerol trioctanoate |
| Chemical data | |
| Formula | C27H50O6 |
| Molar mass | 470.68 g · mol−1[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Caprylidene (trade name Axona) is a medical food that was approved in March 2009 by the U.S. Food and Drug Administration for the "clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease".[1] Glucose metabolism by the brain is impaired in Alzheimer's disease, and it is proposed that ketone bodies may provide an alternative energy source. Caprylidene is a powdered form of caprylic triglyceride, a medium chain triglyceride (MCT) in which three molecules of caprylic acid are esterified with glycerol.[2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 35px | This drug article relating to the nervous system is a stub. You can help ssf by expanding it. |
- ↑ FDA-Approved Drugs 2009: Axona (caprylidene) CenterWatch. Cited 30 November 2009.
- ↑ Axona Drugs.com. Cited 30 November 2009.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Alzheimer's disease
- Enteral feeding
- Triglycerides
- Nervous system drug stubs
- 2Fix
